Subject Index

β-Adrenergic receptor, cystic fibrosis modifier gene 80
Airway clearance, see Physiotherapy, cystic fibrosis
Airway potential difference assays
approaches 104, 105
limitations 105, 106
multicenter studies 105
perfusion rate and duration 105
solution temperature 105

cystic fibrosis
chloride transport 103, 104
sodium transport 103
diagnostic application 106
electrophysiology 102, 103
lower airway measurements 107
physiologic process assessment 106, 107
prognostic application 106
prospects 107, 108
therapy assessment 107

Allergic bronchopulmonary aspergillosis (ABPA)
clinical features 168, 169
diagnostic criteria 166–168
epidemiology 166, 167
immunopathogenesis 167, 168
natural history 167
pathogen species 166, 169
predisposing factors in cystic fibrosis 167
treatment 169–171

Amiloride-sensitive epithelial sodium channel (ENaC)

Airway surface liquid volume depletion and increased sodium absorption 117–120
cystic fibrosis modifier gene 81
cystic fibrosis transmembrane conductance regulator interactions 47, 55
inhibition in cystic fibrosis management 217
transgenic mice 90, 91

Animal models, cystic fibrosis
ferret, prospects 91
mice, see Mouse models, cystic fibrosis

Antibiotic therapy
aminoglycoside antibiotic therapy for cystic fibrosis class I gene mutations 212, 213
Burkholderia cepacia complex 147
chronic suppressive therapy 181
dry-powder formulations 183, 184
macrolide antibiotics for anti-inflammatory therapy 190, 191
nontuberculous mycobacteria infection 163, 164
Pseudomonas aeruginosa early infection 181
pulmonary exacerbations 181, 182
Staphylococcus aureus 155, 156, 180, 181
Stenotrophomonas maltophilia 149, 150

Anti-inflammatory agents
antiproteases 189, 190
corticosteroids
inhaled 188
oral 188
cyclosporine 191
DNase 190
ibuprofen 188, 189
intravenous immunoglobulin 192
leukotriene receptor antagonists 189
macrolide antibiotics 190, 191
methotrexate 191, 192
prospects for development 192
screening 187, 188

α1-Antitrypsin
anti-inflammatory therapy 190
cystic fibrosis modifier gene 79

Arthropathy, cystic fibrosis 270, 305
Ascites, management 257, 258
Aspergillosis, see Allergic bronchopulmonary aspergillosis
ATP-binding cassette proteins, see also Cystic fibrosis transmembrane conductance regulator
electron crystallography of eukaryotic protein structures 35
nucleotide-binding domains in prokaryotes 32, 33
X-ray crystallography of prokaryotic proteins 34, 35

BAG-1, cystic fibrosis transmembrane conductance regulator expression chaperone 23
Bicarbonate/chloride exchanger, cystic fibrosis transmembrane conductance regulator interactions 47, 48
Bicarbonate ion, cystic fibrosis transmembrane conductance regulator permeation 31
Bikunin, amiloride-sensitive epithelial sodium channel inhibition 217
Biliary disease, cystic fibrosis 258, 259
Bisphosphonates, cystic fibrosis bone disease management 275, 276
Bone disease, cystic fibrosis bone mineral density reduction and risk factors 270, 271, 305
clinical manifestations 271
correlation with pulmonary dysfunction 273
etiology chronic infection 275
corticosteroids 274, 275
physical inactivity 274
puberty delay and gonadal failure 273
vitamin D deficiency 274, 297
vitamin K deficiency 274, 297
exercise in prevention 305
genetics 275
histomorphometry 271–273
nutrition in prevention 297
prevalence 271
prevention 319
screening 275
treatment 275, 276
Burkholderia cepacia complex acquisition 147
adherence 183
antibiotic therapy 147
epidemiology of infection in cystic fibrosis 146, 147
genomovars and species 145, 146
identification 145, 146
inflammation in pathogenesis 147, 148
opportunist infection 145
reservoirs 148
Butyrate, ΔF508 cystic fibrosis transmembrane conductance regulator mutant effects 213, 214
Calcium, dietary intake 297
Calcium-activated chloride channel (CaCC) cystic fibrosis modifier gene 81
pharmacological activation in cystic fibrosis management 216
Candidiasis, respiratory infection in cystic fibrosis 166, 171
Carrier screening, cystic fibrosis models
Cystic Fibrosis Clinical Nurse Specialist (CF CNS) best nursing practice recommendations
adolescence 287
children
community care 288
diagnosis 287, 288
inpatient care 288
outpatient care 288
organ transplantation 290
pediatric care transition to adult care 289, 290
pregnancy and fertility 290
terminal disease 290, 291
challenges 286, 287
prospects for care 291
United Kingdom care overview 286
Cystic fibrosis lung disease airway surface liquid volume depletion and increased sodium absorption 117–120
clinical pathological description 116, 117
epithelial sodium channel transgenic mice 90, 91, 117–120
genotype-phenotype correlations with lung function 200
ion transport alteration linkage to deficient mucus transport 117
microbial exacerbation 155
mouse models 88–90
Cystic fibrosis transmembrane conductance regulator (CFTR) anion permeation bicarbonate 31
binding site identification 40
calcium 30, 31
dynamics of selectivity 42, 43
glutathione 31, 43
models 40
selectivity and filter localization 38, 40
ATPase activity 32, 40
constitutive expression 14
developmental expression and regulation 14, 54–58
expression regulation development 55
posttranscriptional regulation 17, 18
prospects for study 18
transcriptional regulation 14–17
fluorescence assays, see Fluorescence assays, cystic fibrosis transmembrane conductance regulator function gene ΔF508 mutant 25–27, 62, 213, 214
discovery 2
mutations classification 4–8, 62
defective protein processing 6, 7, 21, 25–27
defective protein regulation 7
defective protein synthesis 5, 6
overview 4, 61, 62, 212
pharmacological approaches for correction 212–216

Subject Index 325
Cystic fibrosis transmembrane conductance regulator (CFTR) (continued)
prospects for study 8
reduced expression 7, 8, 16
polymorphisms 8, 77, 78
structure 2–4
genotype-phenotype correlations, see Genotype-phenotype correlations, cystic fibrosis
normal protein in cystic fibrosis 316, 317
nucleotide regulation
channel gating 32
mechanism 41
nucleotide-binding domains 32–34, 40, 41
prospects for study 42
phosphorylative regulation 31, 41, 42, 112
protein regulatory function
direct physical interaction with other proteins 46, 47
facilitated interaction with other proteins 47, 48
history of study 45
indirect mechanisms
electrochemical potential alterations 49, 50
paracrine/autocrine function loss 48, 49
structure
membrane-spanning domains 39, 40
overview of domains 29
quaternary structure 30
R domain 41, 42
synthesis, trafficking, and degradation
cell surface targeting 23, 24
chaperones 22, 23
domain assembly in endoplasmic reticulum 22
endocytosis and recycling dynamics 24, 25
therapeutic targeting 320
tissue distribution and function 11–14, 317

Development, see also Infants
cystic fibrosis in infants
airway changes 57
infection 57
pulmonary function tests 56, 57, 195–198
cystic fibrosis transmembrane conductance regulator
defects and disrupted lung development 57, 58
expression 14, 54, 55
gene transfer studies in utero 56

Diabetes
cystic fibrosis related diabetes complications
acute 280
chronic 280
diagnostic criteria 278, 279
epidemiology 278–280
pathophysiology 278, 279
psychological issues 281, 282
pulmonary function impact 280
screening 280–282
treatment
children and adolescents 282
diet 281, 297
insulin therapy 281
organ recipients 282
gestational diabetes in cystic fibrosis 266, 267, 282
Diagnosis, cystic fibrosis
age at diagnosis 69
carrier screening
models
couple-based versus sequential screening 74
preconception versus prenatal screening 74
population-based screening 73–75
classic versus nonclassic disease 69, 70
cystic fibrosis transmembrane conductance regulator gene mutations 70
differential diagnosis 71
nasal potential difference 70
newborn screening 72, 73
prospects for testing 317
related disease 71, 72
sweat chloride test 70
Diet, see Nutrition
Disseminated bronchiectasis, cystic fibrosis related disease 72
Distal ileal obstruction syndrome (DIOS), cystic fibrosis 237, 238
DNA microarray
cystic fibrosis applications
cystic fibrosis transmembrane conductance regulator expression 110, 111
disease biomarkers 111
pharmacogenomics 111
prospects 113
Pseudomonas aeruginosa
pathogenesis 111, 140, 141
overview 109, 110
DNase, anti-inflammatory therapy 190, 317
End-stage cystic fibrosis
nursing care 290, 291
psychological issues 312
respiratory failure terminal care 175
Enteral feeding, cystic fibrosis 296
Epithelial cell specific sodium channel, see Amiloride-sensitive epithelial sodium channel
Essential fatty acids, deficiency in cystic fibrosis 298
Everolimus, immunosuppression in lung transplantation 178
Exercise prescription, see Physiotherapy, cystic fibrosis
Fertility, see also Pregnancy
contraception 265
females 265
males 264
mouse cystic fibrosis models 88
nursing in cystic fibrosis 290
Fibrosing colonopathy, cystic fibrosis 239
Fluorescence assays, cystic fibrosis
transmembrane conductance regulator function applications 93
collisional quenching 93, 94
high-throughput screening 98–100
probes
green fluorescent protein based indicators 96–98
LMQ 95
MEQ 94
MQAE 94
SPQ 93–96
strategies 95, 96
Gastroesophageal reflux disease (GERD), cystic fibrosis 236
Gastrointestinal dysfunction
cancer risks in cystic fibrosis 239
distal ileal obstruction syndrome 237, 238
fibrosing colonopathy 239
gastroesophageal reflux disease 236
intestinal pathophysiology 232, 234, 235
malabsorption 236
meconium ileus
clinical outcome 235, 236
pathophysiology 235
mouse cystic fibrosis models 87, 88
peptic ulcer 237
Gene therapy, cystic fibrosis
assays 224, 225
barriers 222
enhancement 224
prospects 321
pulmonary stem cells 224
target cells 221, 222
viral vectors 222–224
Genotype-phenotype correlations, cystic fibrosis
clinical significance and impact of studies 66
complex alleles 61
cystic fibrosis transmembrane conductance regulator gene mutations 61, 62
gene mutation class correlation 63, 64
infant lung function 200
intermediate phenotypic levels 63
pancreatic insufficiency 243, 244
phenotype variability 62, 64–66
survival 64
Glutathione, cystic fibrosis transmembrane conductance regulator permeation 31, 43
Green fluorescent protein (GFP), halide indicators 96–98
Heat shock proteins, cystic fibrosis transmembrane conductance regulator expression chaperones 23
Hepatic encephalopathy, management 258
Human leukocyte antigen (HLA), cystic fibrosis modifier gene 79, 81
Ibuprofen, anti-inflammatory therapy 188, 189
Immunization
active immunization 182
passive immunization 182
Pseudomonas aeruginosa 138, 139
Infants
airway changes 57
cystic fibrosis treatment impact on pulmonary function 187
diminished airway function in cystic fibrosis 196, 197
gas-trapping tests 199, 200
genotype-phenotype correlations with lung function 200
imaging of cystic fibrosis, see Chest radiography; Computed tomography infection 57, 198
inflammation 198
nutrition 293, 294
physiotherapy
asymptomatic infants 301, 302
head-down postural drainage positions 302
Pseudomonas aeruginosa eradication 181
infection identification bronchoalveolar lavage 132
diagnostic accuracy 132, 133
oropharyngeal cultures 132
serum antibodies with oropharyngeal cultures 132
pulmonary function tests 56, 57, 195–198
Inflammation, see also Anti-inflammatory agents
Burkholderia cepacia complex pathogenesis 147, 148
infection association studies in cystic fibrosis 122, 123
response studies in cystic fibrosis cell culture 124, 125
humans 123, 124
knockout mice 124
nonepithelial cell type participation 125, 126
signaling pathways in cystic fibrosis 126, 128
Interleukin-10 (IL-10), levels in cystic fibrosis 123
Intestine, see Gastrointestinal dysfunction
Inflammation, see also Anti-inflammatory agents
Burkholderia cepacia complex pathogenesis 147, 148
infection association studies in cystic fibrosis 122, 123
response studies in cystic fibrosis cell culture 124, 125
humans 123, 124
knockout mice 124
nonepithelial cell type participation 125, 126
signaling pathways in cystic fibrosis 126, 128
Interleukin-10 (IL-10), levels in cystic fibrosis 123
Jaundice, management 256
Lipoxin A₄ (LXA₄), levels in cystic fibrosis 123, 124, 128, 189
Liver disease, cystic fibrosis cancer risks 259
clinical features 252, 253
complications and management ascites 257, 258
hepatic encephalopathy 258
jaundice 256
splenomegaly 258
varices 256, 257
epidemiology 251
evaluation biopsy 254, 255
endoscopy 254
liver function tests 253
magnetic resonance imaging 253
radionuclide imaging 253, 254
ultrasoundography 253
lung transplantation patient selection 258
modifier genes 81
pathogenesis 251, 252
treatment bile acid therapy 255
liver transplantation 255, 256
Low-frequency forced oscillation technique, pulmonary function testing 203
Lung development, see Development
Lung disease, see Cystic fibrosis lung disease
Lung transplantation chronic rejection 177, 178
immunosuppression 177, 178
liver disease patients 258
morbidity 175, 176
nursing 290
nutrition 297, 298
opportunist infection 178
prospects 320
recipient selection 175
rehabilitation 178
survival 173
Magnetic resonance imaging (MRI)
cystic fibrosis applications 208, 209
liver disease in cystic fibrosis 253
Malabsorption, cystic fibrosis 236
Mannose-binding lectin (MBL), cystic fibrosis modifier gene 80
Meconium ileus clinical outcome 235, 236
pathophysiology 235
Megestrol acetate, appetite stimulation 296
Methicillin-resistant Staphylococcus aureus (MRSA) eradication 157, 158
lung disease exacerbation in cystic fibrosis 155
prevalence in cystic fibrosis 154
prevention of infection 156, 157
prospects for study 158
Methotrexate, anti-inflammatory therapy 191, 192
Microarray, see DNA microarray
Montelukast, anti-inflammatory therapy 189
Mouse models, cystic fibrosis
cystic fibrosis transmembrane conductance regulator knockout mice 84
mutant mice 85–87
epithelial sodium channel transgenic mice 90, 91, 117–120
inflammation response studies 124
knock-in mice 90
phenotypes bone disease 88
fertility 88
intestinal disease 87, 88
lung disease 88–90
pancreatic disease 88
tooth abnormalities 88
tissue targeting 90
transgenic mouse generation 84, 85
Multiple-breath inert gas washout, pulmonary function testing 201–203
Mycobacteria, see Nontuberculous mycobacteria infection

Nasal potential difference (NPD), cystic fibrosis diagnosis 70
Nebulizer, device advances 303
Newborn screening, cystic fibrosis 72, 73
Nitric oxide synthase (NOS), cystic fibrosis modifier genes 80
Nontuberculous mycobacteria infection clinical impact in cystic fibrosis 161, 162
diagnosis 162, 163
epidemiology 160, 161
pathophysiology 161
prospects for study 164
species 160, 161
treatment 163, 164
Nuclear factor-kB (NF-kB)
activation in cystic fibrosis 126
cystic fibrosis transmembrane conductance regulator expression regulation 16
Nucleotide-binding domain (NBD)
ATP-binding cassette proteins
electron crystallography of eukaryotic protein structures 35
prokaryote domains 32, 33
X-ray crystallography of prokaryote proteins 34, 35
cystic fibrosis transmembrane conductance regulator 32–34
head-to-tail dimer 40, 41
mechanism of action 41
Nursing, see Cystic Fibrosis Clinical Nurse Specialist
Nutrition
adolescents and adults 294
appetite stimulants 296
assessment 293
calcium intake 297
cystic fibrosis related diabetes 281, 297
dietary intake maximization 293
enteral tube feeding 296
essential fatty acid deficiency 298
infants and children 293, 294
lump transplant recipients 297, 298
mealtime behavior management 310
pancreatic enzyme replacement therapy
dosing 295
infants 294
overnight feeds 295
preparations 295
ventilated patients 295
pregnancy 297
vitamin supplementation
vitamin A 295
vitamin D 275, 295
vitamin E 296
vitamin K 275, 296
water-soluble vitamins 296
Osteopenia, see Bone disease, cystic fibrosis
Outward rectifying chloride channel (ORCC), cystic fibrosis transmembrane conductance regulator interactions 47
Pancreatic disease, cystic fibrosis
genotype-phenotype correlations in pancreatic insufficiency 243, 244
mouse models 88
pancreatitis
gene mutations 71, 72
recurrent acute and idiopathic chronic pancreatitis 244–247
pathophysiology
intraluminal digestion factors 246
overview 242, 243
primary pancreatic insufficiency 245, 246
recurrent acute and idiopathic chronic pancreatitis 246, 247
secondary pancreatic insufficiency 246
prospects for study 247
Pancreatic enzyme replacement therapy (PERT)
dosing 295
infants 294
overnight feeds 295
preparations 295
ventilated patients 295
PDZ domain proteins, cystic fibrosis transmembrane conductance regulator interactions 47, 48
Pediatric research, ethical and practical difficulties 321
Peptic ulcer, cystic fibrosis 237
4-Phenylbutyrate, ΔF508 cystic fibrosis transmembrane conductance regulator mutant effects 214
Physiotherapy, cystic fibrosis
airway clearance techniques 305, 306
infants
asymptomatic infants 301, 302
head-down postural drainage positions 302
initiation 301
nebulizer device advances 303
optimization 306, 307
physical training
benefits 304
exercise prescription 304
fitness assessment 303, 304
noninvasive ventilation 304, 305
special considerations
acute exacerbation 305
arthropathy 305
diabetes 305
infection control 305
nutrition 305
osteoarthritis 305
supplemental oxygen 305
young children 302, 303
Potassium channels, cystic fibrosis transmembrane conductance regulator interactions 45, 46
Potential difference, see Airway potential difference
Pregnancy, see also Fertility
diabetes in cystic fibrosis 266, 267, 282
long-term effects in cystic fibrosis 267
nursing in cystic fibrosis 290
nutrition 297
obstetric management 268
physiological changes in cystic fibrosis 266, 267
prenatal counselling 267, 268
pulmonary function effects 267
Promoter, cystic fibrosis transmembrane conductance regulator expression regulation studies 14–16
Proteomics
approaches 112, 113
cystic fibrosis applications
biomarkers of lung disease 112
cystic fibrosis transmembrane conductance regulator interactome 112
phosphorylation 112
prospects 113
Pseudomonas aeruginosa
pathogenesis 112, 142
overview 111, 112
Pseudomonas aeruginosa acquisition in cystic fibrosis 133–135, 138
attachment
biofilm formation 139, 140, 183
cup systems 139
flagella 139
therapeutic targeting 182, 183
type IV pili 138, 139
chronic infection in cystic fibrosis 122, 131
DNA microarray studies of pathogenesis 111, 140, 141
early infection identification bronchoalveolar lavage 132
diagnostic accuracy 132, 133
oropharyngeal cultures 132
serum antibodies with oropharyngeal cultures 132
eradication of early infection 181
genome sequence comparisons 140
hypermutation 142, 143
pathogenicity islands 141, 142
proteomics studies 112, 142
strain transmission studies 133–135
Psychological issues, cystic fibrosis adolescents and adherence to treatment 311, 312
children 310, 311
diabetes 281, 282
diagnosis impact on family 309, 310
mealtime behavior management 310
terminal care 312
Puberty, delay in cystic fibrosis 273
Pulmonary function testing
infants 56, 57, 195–198
low-frequency forced oscillation technique 203
multiple-breath inert gas washout 201–203
preschool children 200, 201
raised volume rapid thoracoabdominal technique 196, 197, 199, 201
resistance interrupter technique 200
Radionuclide imaging, liver disease in cystic fibrosis 253, 254
Raised volume rapid thoracoabdominal technique, pulmonary function testing 196, 197, 199, 201
R domain
mechanism of action 42
phosphorylation 41, 42
structure 41
Resistance interrupter technique, pulmonary function testing 200
Respiratory failure
progression 173, 174
terminal care 175
ventilation management 174
Single-nucleotide polymorphisms (SNPs) abundance in human genome 78
cystic fibrosis modifier genes, see also specific genes classification 78–81
gastrointestinal and liver disease 81
study design 81, 82
definition 77
high-throughput analysis 77, 78
Sinusitis, cystic fibrosis related disease 72
Sirolimus, immunosuppression in lung transplantation 178
Sodium/potassium-ATPase, respiratory epithelial ion transport 102, 103
Sodium/proton exchanger, cystic fibrosis transmembrane conductance regulator interactions 48
Splenomegaly, management 258
Staphylococcus aureus, see also Methicillin-resistant Staphylococcus aureus antibiotic therapy 155, 156, 180, 181
chronic infection in cystic fibrosis 153, 154
epidemiology 154
lung disease exacerbation in cystic fibrosis 155
microbiology 154
Stem cell therapy, cystic fibrosis 225, 226
Stenotrophomonas maltophilia antibiotic therapy 149, 150
epidemiology of infection in cystic fibrosis 149
identification 149
opportunistic infection 149
reservoirs 148, 149
taxonomy 150
Sweat chloride test, cystic fibrosis diagnosis 70
Thapsigargin, ΔF508 cystic fibrosis transmembrane conductance regulator mutant effects 214
Transforming growth factor-β (TGF-β), cystic fibrosis modifier gene 80, 81
Tumor necrosis factor-α (TNF-α), cystic fibrosis modifier gene 79
Twin studies, overview 78
Ultrasonography, liver disease in cystic fibrosis 253
Urinary continence, cystic fibrosis patients 265
Varices, management 256, 257
Vasculitis, cystic fibrosis 270
Vitamin A, supplementation in cystic fibrosis 295
Vitamin D deficiency in cystic fibrosis 274, 297
supplementation in cystic fibrosis 275, 295, 296
Vitamin E, supplementation in cystic fibrosis 296
Vitamin K deficiency in cystic fibrosis 274, 297
supplementation in cystic fibrosis 275, 296
Zafirlukast, anti-inflammatory therapy 189